These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15808478)

  • 1. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.
    Wentland MP; Lu Q; Lou R; Bu Y; Knapp BI; Bidlack JM
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2107-10. PubMed ID: 15808478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties.
    Wentland MP; Lou R; Dehnhardt CM; Duan W; Cohen DJ; Bidlack JM
    Bioorg Med Chem Lett; 2001 Jul; 11(13):1717-21. PubMed ID: 11425545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
    Wentland MP; Lou R; Lu Q; Bu Y; VanAlstine MA; Cohen DJ; Bidlack JM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):203-8. PubMed ID: 19027293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic studies on binding of [3H] beta-funaltrexamine ([3H] beta-FNA) to mu opioid receptors.
    Liu-Chen LY; Li S; Holowecky O; Tallarida RJ
    Prog Clin Biol Res; 1990; 328():57-60. PubMed ID: 2154818
    [No Abstract]   [Full Text] [Related]  

  • 5. Syntheses of novel high affinity ligands for opioid receptors.
    Wentland MP; Lou R; Lu Q; Bu Y; Denhardt C; Jin J; Ganorkar R; VanAlstine MA; Guo C; Cohen DJ; Bidlack JM
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2289-94. PubMed ID: 19282177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.
    Wentland MP; VanAlstine M; Kucejko R; Lou R; Cohen DJ; Parkhill AL; Bidlack JM
    J Med Chem; 2006 Sep; 49(18):5635-9. PubMed ID: 16942039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Characterization of Azido Aryl Analogs of IBNtxA for Radio-Photoaffinity Labeling Opioid Receptors in Cell Lines and in Mouse Brain.
    Grinnell SG; Uprety R; Varadi A; Subrath J; Hunkele A; Pan YX; Pasternak GW; Majumdar S
    Cell Mol Neurobiol; 2021 Jul; 41(5):977-993. PubMed ID: 32424771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of naltrexone into mesembrane and investigation of the binding properties of its intermediate derivatives to opioid receptors.
    Konoura K; Fujii H; Imaide S; Gouda H; Hirayama S; Hirono S; Nagase H
    Bioorg Med Chem; 2015 Feb; 23(3):439-48. PubMed ID: 25573119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine.
    Wentland MP; Lu Q; Ganorkar R; Zhang SZ; Jo S; Cohen DJ; Bidlack JM
    Bioorg Med Chem Lett; 2009 Jan; 19(2):365-8. PubMed ID: 19091564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of Beckett-Casy model 3: synthesis of novel naltrexone derivatives with contracted and expanded D-rings and their pharmacology.
    Nagase H; Imaide S; Tomatsu M; Hirayama S; Nemoto T; Sato N; Nakajima M; Nakao K; Mochizuki H; Gouda H; Hirono S; Fujii H
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3801-4. PubMed ID: 20478707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction.
    Fujii H; Osa Y; Ishihara M; Hanamura S; Nemoto T; Nakajima M; Hasebe K; Mochizuki H; Nagase H
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4978-81. PubMed ID: 18755589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers.
    Carliss RD; Keefer JF; Perschke S; Welch S; Rich TC; Weissman AD
    Pharmacol Biochem Behav; 2009 May; 92(3):495-502. PubMed ID: 19463265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of beta-funaltrexamine binding to wild-type and mutant mu-opioid receptors expressed in Chinese hamster ovary cells.
    Spivak CE; Beglan CL
    Synapse; 2004 May; 52(2):123-35. PubMed ID: 15034918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroquinoline derivatives as opioid receptor antagonists.
    Zhang C; Westaway SM; Speake JD; Bishop MJ; Goetz AS; Carballo LH; Hu M; Epperly AH
    Bioorg Med Chem Lett; 2011 Jan; 21(2):670-6. PubMed ID: 21193310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
    Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
    Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: mu, kappa, and putative epsilon opioid receptor antagonists.
    Fujii H; Watanabe A; Nemoto T; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
    Bioorg Med Chem Lett; 2009 Jan; 19(2):438-41. PubMed ID: 19042127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
    Takeuchi K; Holloway WG; McKinzie JH; Suter TM; Statnick MA; Surface PL; Emmerson PJ; Thomas EM; Siegel MG; Matt JE; Wolfe CN; Mitch CH
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5349-52. PubMed ID: 17720493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational analysis of 6α- and 6β-naltrexol and derivatives and relationship to opioid receptor affinity.
    Bayron JA; Deveau AM; Stubbs JM
    J Chem Inf Model; 2012 Feb; 52(2):391-5. PubMed ID: 22263545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.